Small molecule · Agonist of Adenosine A3 receptor (ADORA3) · developed by Can-Fite BioPharma
Namodenoson is an orally bioavailable, synthetic, highly selective agonist of the adenosine A3 receptor, a G protein-coupled receptor highly expressed on various solid tumor cells. By binding and activating this receptor, it is described as deregulating Wnt and NF-kB signaling, which may lead to apoptosis of A3AR-expressing tumor cells. It is being studied in hepatocellular carcinoma and pancreatic cancer, and in patients with cirrhosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05201404 | Phase 3 | Hepatocellular Carcinoma | Recruiting | CANF |
| NCT06387342 | Phase 2 | Pancreatic Adenocarcinoma | Recruiting | CANF |
| NCT02128958 | Phase 2 | Hepatocellular Carcinoma | Completed | CANF |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CirrhosisPancreatic AdenocarcinomaPancreatic CancerHepatocellular Carcinoma
Updated Oct 11, 2026. Something wrong or missing? Report it on the CANF page.
See CANF's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CANF catalysts and pipeline →